Theriva Biologics, Inc. (TOVX)

NYSEAMERICAN: TOVX · Real-Time Price · USD
1.140
-0.070 (-5.79%)
At close: Mar 28, 2025, 4:00 PM
1.260
+0.120 (10.53%)
After-hours: Mar 28, 2025, 5:51 PM EST
-5.79%
Market Cap 3.17M
Revenue (ttm) n/a
Net Income (ttm) -25.65M
Shares Out 2.78M
EPS (ttm) -19.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 28,421
Open 1.190
Previous Close 1.210
Day's Range 1.130 - 1.250
52-Week Range 1.030 - 12.250
Beta 1.16
Analysts Strong Buy
Price Target 6.00 (+426.32%)
Earnings Date May 6, 2025

About TOVX

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the tr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2006
Employees 22
Stock Exchange NYSEAMERICAN
Ticker Symbol TOVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for TOVX stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target
$6.0
(426.32% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

ROCKVILLE, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

11 days ago - GlobeNewsWire

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

– Enrollment completed in VIRAGE Phase 2b clinical trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma (PDAC); topline data expected in Q2 2025 –

24 days ago - GlobeNewsWire

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

ROCKVILLE, Md., March 05, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

25 days ago - GlobeNewsWire

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases i...

4 months ago - GlobeNewsWire

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a clinical-stage company developing therapeutics designed to treat cancer and r...

5 months ago - GlobeNewsWire

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to ...

6 months ago - GlobeNewsWire

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms)  enrolled across 15 sites in Spain and the USA within 21 months –

6 months ago - GlobeNewsWire

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Theriva Biologics and the Universitat Autònoma de Barcelona to receive a total of €2.28 Million to support the THERICEL project, a suspension cell platform for manufacturing viral-based therapies Ther...

6 months ago - GlobeNewsWire

Theriva Biologics Announces Reverse Stock Split

ROCKVILLE, Md., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of hig...

8 months ago - GlobeNewsWire

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

ROCKVILLE, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related dise...

8 months ago - GlobeNewsWire

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in...

11 months ago - GlobeNewsWire

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in...

11 months ago - GlobeNewsWire

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

- Reported topline data from the investigator sponsored Phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma; trial results were determined to be positive by the s...

11 months ago - GlobeNewsWire

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

1 year ago - GlobeNewsWire

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

–Phase 1 trial in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee–

1 year ago - GlobeNewsWire

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft –

1 year ago - GlobeNewsWire

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

1 year ago - GlobeNewsWire

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

1 year ago - Seeking Alpha

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

– The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adeno...

1 year ago - GlobeNewsWire

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

ROCKVILLE, Md., March 19, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

1 year ago - GlobeNewsWire

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

ROCKVILLE, Md., March 11, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases ...

1 year ago - GlobeNewsWire

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

The independent data monitoring committee (IDMC) recommended the continuation of VIRAGE with no safety concerns raised; VIRAGE remains on track to complete enrollment in the first half of 2024 The ind...

1 year ago - GlobeNewsWire

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

ROCKVILLE, Md., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related disea...

1 year ago - GlobeNewsWire

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Theriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Results Conference Call November 13, 2023 8:30 AM ET Company Participants Steve Shallcross - Chief Executive and CFO Dr. Manel Cascalló - General Director,...

1 year ago - Seeking Alpha

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track to complete enrollment in the first half of 2024; mult...

1 year ago - GlobeNewsWire